The purpose of this study is to evaluate effectiveness of albendazole in the treatment of the asymptomatic infection with the parasite Toxocara in children. Treatment response is defined as a reduction in the number of eosinophils in blood. The study drug will be compared to placebo and randomly assigned in a double blind manner. Follow up will be prospective. 50 children (25 per group) will be enrolled in the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
45
Albendazole 10 - 15 mg/kg/day BID for 15 days
Placebo BID for 15 days
Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires
Buenos Aires, Argentina
Mean absolute reduction in eosinophil count from baseline
Time frame: 12 months after treatment
Reduction in eosinophil count in more than 60% from baseline
Time frame: 1 year
Incidence of adverse drug events
Time frame: 3, 6, 9 and 12 months after treatment
Mean absolute reduction in eosinophil count
Time frame: 3, 6, 9 months after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.